Profile data is unavailable for this security.
About the company
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
- Revenue in USD (TTM)0.00
- Net income in USD-5.06m
- Incorporated2023
- Employees1.00
- LocationKairos Pharma Ltd2355 Westwood Blvd. #139LOS ANGELES 90064United StatesUSA
- Phone+1 (818) 404-5541
- Fax+1 (845) 818-3588
- Websitehttps://kairospharma.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ainos Inc | 113.04k | -14.96m | 12.15m | 44.00 | -- | 0.8304 | -- | 107.48 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 12.41m | -- | -- | 0.1392 | -- | 4.92 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| BioCardia Inc | 0.00 | -8.54m | 12.52m | 17.00 | -- | 4.77 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 12.55m | 1.00 | -- | 0.9505 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.58m | 82.00 | -- | 0.3613 | -- | 1.34 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| NewcelX AG | 0.00 | -6.21m | 12.58m | 1.00 | -- | 0.4066 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 13.12m | 1.00 | -- | 1.71 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| Cocrystal Pharma Inc | 0.00 | -9.67m | 13.16m | 11.00 | -- | 1.62 | -- | -- | -0.9356 | -0.9356 | 0.00 | 0.5881 | 0.00 | -- | -- | 0.00 | -72.50 | -43.29 | -83.33 | -45.24 | -- | -- | -- | -4,873.78 | -- | -- | 0.00 | -- | -- | -- | 2.67 | -- | -43.98 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 13.33m | 4.00 | -- | 4.29 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -13.62m | 13.48m | 85.00 | -- | 2.88 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| Curis Inc | 11.65m | -36.56m | 13.70m | 33.00 | -- | -- | -- | 1.18 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 13.89m | 5.00 | -- | 0.7585 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 67.94k | 0.33% |
| Geode Capital Management LLCas of 30 Sep 2025 | 65.80k | 0.32% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 63.88k | 0.31% |
| Two Sigma Investments LPas of 30 Sep 2025 | 45.79k | 0.22% |
| Aptus Capital Advisors LLCas of 30 Sep 2025 | 44.29k | 0.21% |
| SevenBridge Financial Group LLCas of 31 Dec 2025 | 44.29k | 0.21% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 24.90k | 0.12% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 24.10k | 0.12% |
| Quadrature Capital Ltd.as of 30 Sep 2025 | 14.89k | 0.07% |
| XTX Markets LLCas of 30 Sep 2025 | 12.41k | 0.06% |
